Stéphanie Baulac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stéphanie Baulac has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Eric Leguern
Département de Génétique Médicale, Assistance Publique - Hôpitaux de Paris (APHP) Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
22 shared publicationsMichel Baulac
Inserm, U1127, ICM, Paris, France
15 shared publicationsMathilde Chipaux
Pediatric Neurosurgery Department, CCMR Epilepsies Rares, European Reference Network EpiCare Member, Rothschild Foundation Hospital, Paris, France
14 shared publicationsFabienne Picard
Department of Clinical Neurosciences, University Hospitals and Medical School of Geneva , 1205 Geneva
13 shared publicationsEric LeGuern
12 shared publicationsSara Baldassari
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
12 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 30 March 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (4) , 782-797
Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies
Small nuclear RNAs (snRNAs) are essential components of the spliceosome. De novo variants in snRNA genes RNU4-2 (ReNU syndrome), RNU5B-1 and RNU2-2 have been linked to dominant neurodevelopmental disorders (NDDs), revealing a large unexpected contribution of noncoding RNA genes to genetic diseases. Here, through international collaborations, we analyze systematically 200 potentially functional snRNA genes in a French cohort of 34,329 people with rare disorders. We report RNU2-2 variants in 141 individuals, including 35 with recurrent dominant pathogenic variants and 91 affected members from 73 families with biallelic variants. Recessive RNU2-2 NDD is at least twice as frequent as the dominant form and often involves a de novo variant in trans with an inherited allele, consistent with the high mutability of snRNA genes. Dominant and recessive RNU2-2 NDDs share overlapping clinical features, with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our results support a gradient-of-impact model bridging dominant and recessive inheritance, and establish RNU2-2 variants as a principal contributor to NDDs, nearly as prevalent as ReNU syndrome.
- 30 March 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (4) , 782-797
Top Cited PapersOpen AccessSystematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies
Small nuclear RNAs (snRNAs) are essential components of the spliceosome. De novo variants in snRNA genes RNU4-2 (ReNU syndrome), RNU5B-1 and RNU2-2 have been linked to dominant neurodevelopmental disorders (NDDs), revealing a large unexpected contribution of noncoding RNA genes to genetic diseases. Here, through international collaborations, we analyze systematically 200 potentially functional snRNA genes in a French cohort of 34,329 people with rare disorders. We report RNU2-2 variants in 141 individuals, including 35 with recurrent dominant pathogenic variants and 91 affected members from 73 families with biallelic variants. Recessive RNU2-2 NDD is at least twice as frequent as the dominant form and often involves a de novo variant in trans with an inherited allele, consistent with the high mutability of snRNA genes. Dominant and recessive RNU2-2 NDDs share overlapping clinical features, with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our results support a gradient-of-impact model bridging dominant and recessive inheritance, and establish RNU2-2 variants as a principal contributor to NDDs, nearly as prevalent as ReNU syndrome.
- Open Access
- 6 March 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (10) , 3631-3646
Mosaic human cortical organoids model mTOR-related focal cortical dysplasia through DEPDC5 deletion
Focal cortical dysplasia type II (FCDII), a major cause of pediatric drug-resistant focal epilepsy, results from brain somatic variants in mTOR pathway genes, including germline and somatic second-hit loss-of-function variants in the mTOR repressor DEPDC5. Here, we present a proof-of-concept model of DEPDC5 two-hit inactivation mosaicism using patient-derived human cortical organoids (hCOs). Mosaic hCOs displayed increased mTOR activity that was rescued by the mTOR inhibitor rapamycin. Mosaic hCOs also exhibited dysmorphic-like neurons and enhanced neuronal excitability, recapitulating key FCDII pathology hallmarks. Single-cell transcriptomics across three developmental stages revealed aberrant differentiation trajectories leading to premature upper-layer neuron generation, upregulated Notch and Wnt signaling pathways in neural progenitors, and altered expression of synaptic- and epilepsy-associated genes in excitatory neurons. In addition, we identified cell-autonomous alterations in metabolism and translation in mosaic DEPDC5 two-hit hCOs. This study provides novel insights into how DEPDC5 deficiency perturbs human corticogenesis, highlighting that mosaic biallelic inactivation of the gene is necessary for FCDII pathogenesis.
- 6 March 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (10) , 3631-3646
Open AccessMosaic human cortical organoids model mTOR-related focal cortical dysplasia through DEPDC5 deletion
Focal cortical dysplasia type II (FCDII), a major cause of pediatric drug-resistant focal epilepsy, results from brain somatic variants in mTOR pathway genes, including germline and somatic second-hit loss-of-function variants in the mTOR repressor DEPDC5. Here, we present a proof-of-concept model of DEPDC5 two-hit inactivation mosaicism using patient-derived human cortical organoids (hCOs). Mosaic hCOs displayed increased mTOR activity that was rescued by the mTOR inhibitor rapamycin. Mosaic hCOs also exhibited dysmorphic-like neurons and enhanced neuronal excitability, recapitulating key FCDII pathology hallmarks. Single-cell transcriptomics across three developmental stages revealed aberrant differentiation trajectories leading to premature upper-layer neuron generation, upregulated Notch and Wnt signaling pathways in neural progenitors, and altered expression of synaptic- and epilepsy-associated genes in excitatory neurons. In addition, we identified cell-autonomous alterations in metabolism and translation in mosaic DEPDC5 two-hit hCOs. This study provides novel insights into how DEPDC5 deficiency perturbs human corticogenesis, highlighting that mosaic biallelic inactivation of the gene is necessary for FCDII pathogenesis.
- Open Access
Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies
Variants in spliceosomal small nuclear RNA (snRNA) genes RNU4-2 (ReNU syndrome), RNU5B-1 , and RNU2-2 have recently been linked to dominant neurodevelopmental disorders (NDDs), revealing a major, previously overlooked role for noncoding snRNAs in human disease. Here, we systematically analysed 200 potentially functional snRNA genes in a French cohort comprising 26,911 individuals with rare disorders and through international collaborations. We identify de novo and biallelic variants in RNU2-2 associated with both dominant and recessive NDDs in 126 individuals from 108 unrelated families. Recessive RNU2-2 NDD is at least twice as frequent as the dominant NDD caused by n.4G>A and n.35A>G, and often arises from a de novo variant in trans with an inherited allele, reflecting the high mutability of snRNA genes. Dominant and recessive RNU2-2 -NDDs share overlapping clinical features with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our findings support a gradient-of-impact model and a continuum between dominant and recessive inheritance, establishing RNU2-2 variants as a frequent cause of NDDs, nearly as prevalent as ReNU syndrome.
Open AccessSystematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies
Variants in spliceosomal small nuclear RNA (snRNA) genes RNU4-2 (ReNU syndrome), RNU5B-1 , and RNU2-2 have recently been linked to dominant neurodevelopmental disorders (NDDs), revealing a major, previously overlooked role for noncoding snRNAs in human disease. Here, we systematically analysed 200 potentially functional snRNA genes in a French cohort comprising 26,911 individuals with rare disorders and through international collaborations. We identify de novo and biallelic variants in RNU2-2 associated with both dominant and recessive NDDs in 126 individuals from 108 unrelated families. Recessive RNU2-2 NDD is at least twice as frequent as the dominant NDD caused by n.4G>A and n.35A>G, and often arises from a de novo variant in trans with an inherited allele, reflecting the high mutability of snRNA genes. Dominant and recessive RNU2-2 -NDDs share overlapping clinical features with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our findings support a gradient-of-impact model and a continuum between dominant and recessive inheritance, establishing RNU2-2 variants as a frequent cause of NDDs, nearly as prevalent as ReNU syndrome.
- Open Access
Mosaic human cortical organoids model mTOR-related focal cortical dysplasia through DEPDC5 loss-of-function
Focal cortical dysplasia type II (FCDII), a leading cause of pediatric drug-resistant focal epilepsy, results from brain somatic variants in genes of the mTOR pathway, including germline and somatic second-hit loss-of-function variants in the mTOR repressor DEPDC5 . Here, we investigated the effects of mosaic DEPDC5 two-hit variants on cortical development and neuronal activity using patient-derived human cortical organoids (hCOs). Mosaic hCOs displayed increased mTOR activity and altered neural rosette densities, which were both rescued by treatment with the mTOR inhibitor rapamycin. In addition, mosaic hCOs presented dysmorphic-like neurons and increased neuronal excitability, recapitulating FCDII pathology. Longitudinal single-cell transcriptomics at three developmental stages revealed altered neuronal differentiation, dysregulated expression of genes associated with the Notch and Wnt pathways in neural progenitors, and of synaptic- and epilepsy-associated genes in excitatory neurons. We further identified cell-autonomous alterations in metabolism and translation in mosaic two-hit hCOs. This study provides novel insights into the consequences of mosaic biallelic DEPDC5 deficiency on corticogenesis in the context of FCDII, highlighting both autonomous and non-cell autonomous effects.
Open AccessMosaic human cortical organoids model mTOR-related focal cortical dysplasia through DEPDC5 loss-of-function
Focal cortical dysplasia type II (FCDII), a leading cause of pediatric drug-resistant focal epilepsy, results from brain somatic variants in genes of the mTOR pathway, including germline and somatic second-hit loss-of-function variants in the mTOR repressor DEPDC5 . Here, we investigated the effects of mosaic DEPDC5 two-hit variants on cortical development and neuronal activity using patient-derived human cortical organoids (hCOs). Mosaic hCOs displayed increased mTOR activity and altered neural rosette densities, which were both rescued by treatment with the mTOR inhibitor rapamycin. In addition, mosaic hCOs presented dysmorphic-like neurons and increased neuronal excitability, recapitulating FCDII pathology. Longitudinal single-cell transcriptomics at three developmental stages revealed altered neuronal differentiation, dysregulated expression of genes associated with the Notch and Wnt pathways in neural progenitors, and of synaptic- and epilepsy-associated genes in excitatory neurons. We further identified cell-autonomous alterations in metabolism and translation in mosaic two-hit hCOs. This study provides novel insights into the consequences of mosaic biallelic DEPDC5 deficiency on corticogenesis in the context of FCDII, highlighting both autonomous and non-cell autonomous effects.
- Open Access
- 2 June 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 212, 106985
DEPDC5 regulates the strength of excitatory synaptic transmission by interacting with ubiquitin-specific protease 46
- 2 June 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 212, 106985
Open AccessDEPDC5 regulates the strength of excitatory synaptic transmission by interacting with ubiquitin-specific protease 46
- Top Cited PapersOpen Access
- 16 May 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (6) , 1374-1388
Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption
The major spliceosome contains five small nuclear RNAs (snRNAs; U1, U2, U4, U5 and U6) essential for splicing. Variants in RNU4-2, encoding U4, cause a neurodevelopmental disorder called ReNU syndrome. We investigated de novo variants in 50 snRNA-encoding genes in a French cohort of 23,649 individuals with rare disorders and gathered additional cases through international collaborations. Altogether, we identified 145 previously unreported probands with (likely) pathogenic variants in RNU4-2 and 21 individuals with de novo and/or recurrent variants in RNU5B-1 and RNU5A-1, encoding U5. Pathogenic variants typically arose de novo on the maternal allele and cluster in regions critical for splicing. RNU4-2 variants mainly localize to two structures, the stem III and T-loop/quasi-pseudoknot, which position the U6 ACAGAGA box for 5′ splice site recognition and associate with different phenotypic severity. RNU4-2 variants result in specific defects in alternative 5′ splice site usage and methylation patterns (episignatures) that correlate with variant location and clinical severity. This study establishes RNU5B-1 as a neurodevelopmental disorder gene, suggests RNU5A-1 as a strong candidate and highlights the role of de novo variants in snRNAs.
- 16 May 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (6) , 1374-1388
Top Cited PapersOpen AccessDominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption
The major spliceosome contains five small nuclear RNAs (snRNAs; U1, U2, U4, U5 and U6) essential for splicing. Variants in RNU4-2, encoding U4, cause a neurodevelopmental disorder called ReNU syndrome. We investigated de novo variants in 50 snRNA-encoding genes in a French cohort of 23,649 individuals with rare disorders and gathered additional cases through international collaborations. Altogether, we identified 145 previously unreported probands with (likely) pathogenic variants in RNU4-2 and 21 individuals with de novo and/or recurrent variants in RNU5B-1 and RNU5A-1, encoding U5. Pathogenic variants typically arose de novo on the maternal allele and cluster in regions critical for splicing. RNU4-2 variants mainly localize to two structures, the stem III and T-loop/quasi-pseudoknot, which position the U6 ACAGAGA box for 5′ splice site recognition and associate with different phenotypic severity. RNU4-2 variants result in specific defects in alternative 5′ splice site usage and methylation patterns (episignatures) that correlate with variant location and clinical severity. This study establishes RNU5B-1 as a neurodevelopmental disorder gene, suggests RNU5A-1 as a strong candidate and highlights the role of de novo variants in snRNAs.
- Top Cited PapersOpen Access
- 30 April 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (5) , 964-972
Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia
Focal cortical dysplasia type II (FCDII) is a cortical malformation causing refractory epilepsy. FCDII arises from developmental somatic activating mutations in mTOR pathway genes, leading to focal cortical dyslamination and abnormal cytomegalic cells. Which cell types carry pathogenic mutations and how they affect cell-type-specific transcriptional programs remain unknown. In the present study, we combined several single-nucleus genotyping and transcriptomics approaches with spatial resolution in surgical cortical specimens from patients with genetically mosaic FCDII. Mutations were detected in distinct cell types, including glutamatergic neurons and astrocytes, and a small fraction of mutated cells exhibited cytomegalic features. Moreover, we identified cell-type-specific transcriptional dysregulations in both mutated and nonmutated FCDII cells, including synapse- and neurodevelopment-related pathways, that may account for epilepsy and dysregulation of mitochondrial metabolism pathways in cytomegalic cells. Together, these findings reveal cell-autonomous and non-cell-autonomous features of FCDII that may be leveraged for precision medicine.
- 30 April 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (5) , 964-972
Top Cited PapersOpen AccessSingle-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia
Focal cortical dysplasia type II (FCDII) is a cortical malformation causing refractory epilepsy. FCDII arises from developmental somatic activating mutations in mTOR pathway genes, leading to focal cortical dyslamination and abnormal cytomegalic cells. Which cell types carry pathogenic mutations and how they affect cell-type-specific transcriptional programs remain unknown. In the present study, we combined several single-nucleus genotyping and transcriptomics approaches with spatial resolution in surgical cortical specimens from patients with genetically mosaic FCDII. Mutations were detected in distinct cell types, including glutamatergic neurons and astrocytes, and a small fraction of mutated cells exhibited cytomegalic features. Moreover, we identified cell-type-specific transcriptional dysregulations in both mutated and nonmutated FCDII cells, including synapse- and neurodevelopment-related pathways, that may account for epilepsy and dysregulation of mitochondrial metabolism pathways in cytomegalic cells. Together, these findings reveal cell-autonomous and non-cell-autonomous features of FCDII that may be leveraged for precision medicine.
- Open Access
- 28 April 2025
- Published by EDP Sciences in médecine/sciences
- Vol. 41 (4) , 316-318
Du mosaïcisme cérébral aux crises d’épilepsie
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
- 28 April 2025
- Published by EDP Sciences in médecine/sciences
- Vol. 41 (4) , 316-318
Open AccessDu mosaïcisme cérébral aux crises d’épilepsie
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
- Open Access
- 6 April 2025
- Published by Elsevier in Revue Neurologique
- Vol. 181 (5) , 425-431
Detection of brain somatic mutations from stereo-EEG electrodes in focal epilepsy: Current advances and future perspectives
- 6 April 2025
- Published by Elsevier in Revue Neurologique
- Vol. 181 (5) , 425-431
Open AccessDetection of brain somatic mutations from stereo-EEG electrodes in focal epilepsy: Current advances and future perspectives
- Open Access
- 30 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR
Lesional focal epilepsy (LFE) is a common and severe seizure disorder caused by epileptogenic lesions, including malformations of cortical development (MCD) and low-grade epilepsy-associated tumors (LEAT). Understanding the genetic etiology of these lesions can inform medical and surgical treatment. We conducted a somatic variant enrichment mega-analysis in brain tissue from 1386 individuals who underwent epilepsy surgery, including 599 previously unpublished individuals with ultra-deep ( > 1600x) targeted panel sequencing. Here we confirm four known associations (BRAF, SLC35A2, MTOR, PTPN11), support eight associations without prior statistical support (FGFR1, PIK3CA, AKT3, NF1, PTEN, RHEB, KRAS, NRAS), and identify novel associations for two genes, DYRK1A and EGFR. Both novel genes show specific histopathological phenotypes, interact with LFE genes and pathways, and may represent promising candidates as biomarkers and potentially druggable targets.
- 30 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
Open AccessAnalysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR
Lesional focal epilepsy (LFE) is a common and severe seizure disorder caused by epileptogenic lesions, including malformations of cortical development (MCD) and low-grade epilepsy-associated tumors (LEAT). Understanding the genetic etiology of these lesions can inform medical and surgical treatment. We conducted a somatic variant enrichment mega-analysis in brain tissue from 1386 individuals who underwent epilepsy surgery, including 599 previously unpublished individuals with ultra-deep ( > 1600x) targeted panel sequencing. Here we confirm four known associations (BRAF, SLC35A2, MTOR, PTPN11), support eight associations without prior statistical support (FGFR1, PIK3CA, AKT3, NF1, PTEN, RHEB, KRAS, NRAS), and identify novel associations for two genes, DYRK1A and EGFR. Both novel genes show specific histopathological phenotypes, interact with LFE genes and pathways, and may represent promising candidates as biomarkers and potentially druggable targets.